What is scope of the report?

The base year for the study has been considered 2019, historic year 2014 and 2018. Read More

What are the significant segments operating in the market?

Market is segmented on the basis. Read More

What are the vital market dynamics?

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. Read More

What does a company profile includes?

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering. Read More

Global Breast Cancer Liquid Biopsy Market by Circulating Biomarkers (Circulating Tumor Cells, Cell-free DNA, others), End User, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2018 to 2025

Publish Date: Mar, 2019
Report ID: 376049
Category: Healthcare
Pages: 0

$4700

Global breast cancer liquid biopsy market is expected to reach USD 147.07 Million in 2017 to USD 879.41 Million by 2025 at a CAGR of 25.37% from 2018 to 2025. The rising prevalence of cancer cases, high demand and increasing preference for advanced therapies in cancer treatment by physicians are contributing to the growth of the market.

Market Overview:

The liquid biopsy is a fast evolving substitute for conventional tumor biopsies. It is developed to acquire the most amount of molecular information about cancer with less surgical invasion. With rapid advancements in NGS technology, liquid biopsies are estimated to take prime position in cancer-related probe and investigation. It is used for cancer diagnosis and treatment monitoring. This procedure involves the detection of molecular cancer biomarkers in the biological fluids. In this, samples of biological fluids, such as blood, urine, serum, and saliva are taken and then enriched by using different techniques, such as next-generation sequencing (NGS), and polymerase chain reaction (PCR) to detect the mutations causing cancer.

Report Description:

The base year for the study has been considered 2017, the historic year 2015 and 2016 and, the forecast period considered is from 2018 to 2025. The breast cancer liquid biopsy market is analyzed by value (USD Million).
The study delivers a comprehensive analysis of global breast cancer liquid biopsy market by circulating biomarker, end user and regions.
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2018 to 2025.
Porter’s Five Forces model is used to recognize the competitive scenario in the global Breast Cancer Liquid Biopsy market. This report incorporates the industry analysis which is focused on providing an extensive view of the breast cancer liquid biopsy market.
The study also includes attractiveness analysis circulating biomarker, end user, and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
The report provides company profile of the key players operating in the breast cancer liquid biopsy market and a comparative analysis based on their business overviews, product offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
The market estimates have been evaluated by considering the effect of different political, economic, social, technological and legal factors which are based on our extensive secondary research, primary research, and in-house databases.

Market Dynamics:

Drivers:

Increasing preference for non-invasive procedures
Initiatives are undertaken by governments and global health organizations
Technological advancements for better diagnosis
Availability of funding for liquid biopsy R&D

Restraints:

Low sensitivity and specificity of the test

Opportunities:

Growing awareness and interest in liquid biopsy

Challenges:

Unclear regulatory and reimbursement scenario

Global Breast Cancer Liquid Biopsy Market Key Findings:

All the segments have been analyzed on global, regional and country basis. The study includes an analysis of more than 30 countries for each segment.

Segmentation Analysis:

The breast cancer liquid biopsy market is segmented by circulating biomarker and end user.

The circulating biomarkers segment is classified into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment was dominating the market and was valued at around USD 61.74 million in 2017. Due to its occurrence in other body fluids along with the blood of cancer patients and the real-time results obtained by the analysis of cfDNA are the major factors contributing to the growth of cfDNA in the breast cancer liquid biopsy market.
The end-user segment is divided into laboratories, hospitals and physician laboratories, and other end users. Reference laboratories segment held the largest market share of 41.37% in 2017. Availability of advanced genetic testing equipment has increased the volume of liquid biopsy test samples to reference laboratories.

Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and the Middle East and Africa. North America region is dominating the global breast cancer liquid biopsy market with USD 69.09 Million in 2017 whereas the Asia Pacific is expected to register the highest CAGR in the assessment period.

North America is dominating the market owing to easy accessibility, and high adoption of PCR and NGS among healthcare professionals and the increasing incidence of breast cancer are driving the demand in the region.
Asia Pacific is anticipated to witness the highest growth in the forecast period. Infrastructural developments, rising penetration of cutting-edge diagnostic technologies and the growing focus of global life science companies in this region are propelling the growth in the region.

Global Breast Cancer Liquid Biopsy Market Competitive Analysis:

Key players in the breast cancer liquid biopsy market are Bio-Rad Laboratories Inc., Janssen Diagnostics, Biocept Inc., Guardant Health, Inc., QIAGEN, Myriad Genetics, Roche AG, Trovagene Inc., Adaptive Biotechnologies, Epic Sciences, Cynvenio Biosystems, Inc., Illumina, Inc., Menarini Silicon Biosystems, MDxHealth, Sysmex Inostics GmbH, Genomic Health, NeoGenomics Laboratories, Inc., Thermo Fisher Scientific Inc., Fluxion Biosciences, Inc, Isogen Life Science B.V. and others. Market participants are engaged in various strategies to increase their footprints in the market. For instance, in August 2017, Cynvenio Biosystems, Inc. launched ClearID HER2 Expression Test. This new test allows doctors to perform real-time monitoring and analysis of HER2 levels in their patients without using tissue biopsy.

This study forecasts revenue and volume growth at global, regional, and country levels from 2015 to 2025. Fior Market Research has segmented the global breast cancer liquid biopsy market by below-mentioned segments:

Global Breast Cancer Liquid Biopsy Market, By Circulating Biomarker:

Circulating Tumor Cells (CTCs)
Cell-free DNA (cfDNA)
Extracellular Vesicles (EVs)
Other Circulating Biomarkers

Global Breast Cancer Liquid Biopsy Market, By End User:

Reference Laboratories
Hospitals and Physician Laboratories
Other End Users

Global Breast Cancer Liquid Biopsy Market, By Regions:

North America
- The U.S.
- Canada
- Mexico
Europe
- Germany
- France
- Sweden
- Netherlands
- U.K.
- Italy
- Spain
- Turkey
- Switzerland
- Belgium
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- South Korea
- Australia
- Singapore
- Malaysia
- Thailand
- Indonesia
- Philippines
- Rest of Asia-Pacific
South America
- Brazil
- Argentina
- Colombia
- Rest of South America
The Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of The Middle East and Africa

*All our reports are customizable as per customer requirements

Request Sample Request for Customization

1. Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Research Scope
1.4. Currency

2. Research Methodology and Assumptions

3. Executive Summary

4. Premium Insights
4.1. Porter’s Five Forces Analysis
4.2. Value Chain Analysis
4.3. Top Investment Pockets
4.3.1. Market attractiveness analysis by circulating biomarker
4.3.2. Market attractiveness analysis by end user
4.3.3. Market attractiveness analysis by region
4.4. Industry Trends

5. Market Dynamics
5.1. Market Evaluation
5.2. Drivers
5.2.1. Increasing Preference for Non-Invasive Procedures
5.2.2. Initiatives Undertaken by Governments and Global Health Organizations
5.2.3. Technological Advancements for Better Diagnosis
5.2.4. Availability of Funding for Liquid Biopsy R&D
5.3. Restraints
5.3.1. Low Sensitivity and Specificity of the Test
5.3.2. Slower Approval Procedures
5.4. Opportunities
5.4.1. Growing Awareness and Interest in Liquid Biopsy
5.5. Challenges
5.5.1. Unclear Regulatory and Reimbursement Scenario

6. Global Breast Cancer Liquid Biopsy Market Analysis and Forecast, By Circulating Biomarker
6.1. Segment Overview
6.2. Circulating Tumor Cells (CTCs)
6.3. Cell-free DNA (cfDNA)
6.4. Extracellular Vesicles (EVs)
6.5. Other Circulating Biomarkers

7. Global Breast Cancer Liquid Biopsy Market Analysis and Forecast, By End User
7.1. Segment Overview
7.2. Reference Laboratories
7.3. Hospitals and Physician Laboratories
7.4. Other End Users

8. Global Breast Cancer Liquid Biopsy Market Analysis and Forecast, By Regional Analysis
8.1. Segment Overview
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. Sweden
8.3.4. Netherlands
8.3.5. U.K.
8.3.6. Italy
8.3.7. Spain
8.3.8. Turkey
8.3.9. Switzerland
8.3.10. Belgium
8.3.11. Rest of Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. South Korea
8.4.5. Australia
8.4.6. Singapore
8.4.7. Malaysia
8.4.8. Thailand
8.4.9. Indonesia
8.4.10. Philippines
8.4.11. Rest of Asia-Pacific
8.5. South America
8.5.1. Brazil
8.5.2. Argentina
8.5.3. Colombia
8.5.4. Rest of South America
8.6. Middle East and Africa
8.6.1. Saudi Arabia
8.6.2. UAE
8.6.3. Egypt
8.6.4. Nigeria
8.6.5. South Africa
8.6.6. Rest of Middle East and Africa

9. Global Breast Cancer Liquid Biopsy Market-Competitive Landscape
9.1. Overview
9.2. Market Share of Key Players in the Breast Cancer Liquid Biopsy Market
9.2.1. Global Company Market Share
9.2.2. North America Company Market Share
9.2.3. Europe Company Market Share
9.2.4. APAC Company Market Share
9.3. Competitive Situations and Trends
9.3.1. Product Launches and Developments
9.3.2. Partnerships, Collaborations, and Agreements
9.3.3. Mergers & Acquisitions
9.3.4. Expansions

10. Company Profiles
10.1. Bio-Rad Laboratories Inc.
10.1.1. Business Overview
10.1.2. Company Snapshot
10.1.3. Company Market Share Analysis
10.1.4. Company Product Portfolio
10.1.5. Recent Developments
10.1.6. SWOT Analysis
10.2. Janssen Diagnostics
10.2.1. Business Overview
10.2.2. Company Snapshot
10.2.3. Company Market Share Analysis
10.2.4. Company Product Portfolio
10.2.5. Recent Developments
10.2.6. SWOT Analysis
10.3. Biocept Inc.
10.3.1. Business Overview
10.3.2. Company Snapshot
10.3.3. Company Market Share Analysis
10.3.4. Company Product Portfolio
10.3.5. Recent Developments
10.3.6. SWOT Analysis
10.4. Guardant Health, Inc.
10.4.1. Business Overview
10.4.2. Company Snapshot
10.4.3. Company Market Share Analysis
10.4.4. Company Product Portfolio
10.4.5. Recent Developments
10.4.6. SWOT Analysis
10.5. QIAGEN
10.5.1. Business Overview
10.5.2. Company Snapshot
10.5.3. Company Market Share Analysis
10.5.4. Company Product Portfolio
10.5.5. Recent Developments
10.5.6. SWOT Analysis
10.6. Myriad Genetics
10.6.1. Business Overview
10.6.2. Company Snapshot
10.6.3. Company Market Share Analysis
10.6.4. Company Product Portfolio
10.6.5. Recent Developments
10.6.6. SWOT Analysis
10.7. Roche AG
10.7.1. Business Overview
10.7.2. Company Snapshot
10.7.3. Company Market Share Analysis
10.7.4. Company Product Portfolio
10.7.5. Recent Developments
10.7.6. SWOT Analysis
10.8. Trovagene Inc.
10.8.1. Business Overview
10.8.2. Company Snapshot
10.8.3. Company Market Share Analysis
10.8.4. Company Product Portfolio
10.8.5. Recent Developments
10.8.6. SWOT Analysis
10.9. Adaptive Biotechnologies
10.9.1. Business Overview
10.9.2. Company Snapshot
10.9.3. Company Market Share Analysis
10.9.4. Company Product Portfolio
10.9.5. Recent Developments
10.9.6. SWOT Analysis
10.10. Cynvenio Biosystems, Inc.
10.10.1. Business Overview
10.10.2. Company Snapshot
10.10.3. Company Market Share Analysis
10.10.4. Company Product Portfolio
10.10.5. Recent Developments
10.10.6. SWOT Analysis
10.11. Illumina, Inc.
10.11.1. Business Overview
10.11.2. Company Snapshot
10.11.3. Company Market Share Analysis
10.11.4. Company Product Portfolio
10.11.5. Recent Developments
10.11.6. SWOT Analysis
10.12. Menarini Silicon Biosystems
10.12.1. Business Overview
10.12.2. Company Snapshot
10.12.3. Company Market Share Analysis
10.12.4. Company Product Portfolio
10.12.5. Recent Developments
10.12.6. SWOT Analysis
10.13. NeoGenomics Laboratories, Inc.
10.13.1. Business Overview
10.13.2. Company Snapshot
10.13.3. Company Market Share Analysis
10.13.4. Company Product Portfolio
10.13.5. Recent Developments
10.13.6. SWOT Analysis
10.14. Genomic Health
10.14.1. Business Overview
10.14.2. Company Snapshot
10.14.3. Company Market Share Analysis
10.14.4. Company Product Portfolio
10.14.5. Recent Developments
10.14.6. SWOT Analysis
10.15. Fluxion Biosciences, Inc.
10.15.1. Business Overview
10.15.2. Company Snapshot
10.15.3. Company Market Share Analysis
10.15.4. Company Product Portfolio
10.15.5. Recent Developments
10.15.6. SWOT Analysis
10.16. Thermo Fisher Scientific Inc.
10.16.1. Business Overview
10.16.2. Company Snapshot
10.16.3. Company Market Share Analysis
10.16.4. Company Product Portfolio
10.16.5. Recent Developments
10.16.6. SWOT Analysis
10.17. Isogen Life Science B.V.
10.17.1. Business Overview
10.17.2. Company Snapshot
10.17.3. Company Market Share Analysis
10.17.4. Company Product Portfolio
10.17.5. Recent Developments
10.17.6. SWOT Analysis

List of Table
1. Global Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
2. Global Circulating Tumor Cells Breast Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
3. Global Cell-free DNA Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
4. Global Extracellular Vesicles Breast Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
5. Global Other Circulating Biomarkers Breast Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
6. Global Others Breast Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
7. Global Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
8. Global Reference Laboratories Breast Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
9. Global Hospitals and Physician Laboratories Breast Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
10. Global Other End Users Breast Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
11. Global Breast Cancer Liquid Biopsy Market, By Region, 2015–2025 (USD Million)
12. North America Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
13. North America Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
14. U.S. Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
15. U.S. Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
16. Canada Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
17. Canada Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
18. Mexico Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
19. Mexico Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
20. Europe Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
21. Europe Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
22. Germany Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
23. Germany Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
24. France Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
25. France Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
26. Sweden Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
27. Sweden Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
28. Netherlands Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
29. Netherlands Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
30. U.K. Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
31. U.K. Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
32. Italy Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
33. Italy Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
34. Spain Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
35. Spain Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
36. Turkey Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
37. Turkey Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
38. Switzerland Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
39. Switzerland Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
40. Belgium Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
41. Belgium Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
42. Asia Pacific Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
43. Asia Pacific Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
44. Japan Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
45. Japan Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
46. China Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
47. China Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
48. India Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
49. India Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
50. South Korea Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
51. South Korea Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
52. Australia Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
53. Australia Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
54. Singapore Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
55. Singapore Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
56. Malaysia Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
57. Malaysia Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
58. Thailand Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
59. Thailand Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
60. Indonesia Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
61. Indonesia Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
62. Philippines Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
63. Philippines Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
64. South America Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
65. South America Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
66. Brazil Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
67. Brazil Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
68. Argentina Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
69. Argentina Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
70. Colombia Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
71. Colombia Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
72. Middle East and Africa Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
73. Middle East and Africa Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
74. Saudi Arabia Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
75. Saudi Arabia Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
76. UAE Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
77. UAE Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
78. Egypt Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
79. Egypt Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
80. Nigeria Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
81. Nigeria Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)
82. South Africa Breast Cancer Liquid Biopsy Market, By Circulating Biomarker, 2015–2025 (USD Million)
83. South Africa Breast Cancer Liquid Biopsy Market, By End User, 2015–2025 (USD Million)

List of Figures
1. Global Breast Cancer Liquid Biopsy Market Segmentation
2. Breast Cancer Liquid Biopsy Market: Research Methodology
3. Market Size Estimation Methodology: Bottom-Up Approach
4. Market Size Estimation Methodology: Top-Down Approach
5. Data Triangulation
6. Porter’s Five Forces Analysis
7. Value Chain Analysis
8. Global Breast Cancer Liquid Biopsy Market attractiveness analysis by Circulating Biomarker
9. Global Breast Cancer Liquid Biopsy Market attractiveness analysis by End User
10. Global Breast Cancer Liquid Biopsy Market attractiveness analysis by Region
11. Global Breast Cancer Liquid Biopsy Market: Dynamics
12. Global Breast Cancer Liquid Biopsy Market Share by Circulating Biomarker (2017 & 2025)
13. Global Breast Cancer Liquid Biopsy Market Share by End User (2017 & 2025)
14. Global Breast Cancer Liquid Biopsy Market Share by Regions (2017 & 2025)
15. Global Breast Cancer Liquid Biopsy Market Share by Company (2018)

Research Methodology

Market research is a method of gathering, assessing and deducing data & information about a particular market. Market research is very crucial in these days. The techniques analyze about how a product/service can be offered to the market to its end-customers, observe the impact of that product/service based on the past customer experiences, and cater their needs and demands. Owing to the successful business ventures, accurate, relevant and thorough information is the base for all the organizations because market research report/study offers specific market related data & information about the industry growth prospects, perspective of the existing customers, and the overall market scenario prevailed in past, ongoing present and developing future. It allows the stakeholders and investors to determine the probability of a business before committing substantial resources to the venture. Market research helps in solving the marketing issues challenges that a business will most likely face.

Market research is valuable because of the following reasons:

Market research helps businesses strengthen a company’s position
Market research helps in minimizing the investment risks associated with the businesses in any industry vertical
Market research helps in identifying the potential threats and opportunities associated with the business industry
Market research aids in spotting the emerging trends and facilitates strategic planning in order to stay ahead in the competition

Our research report features both the aspects; qualitative and quantitative. Qualitative part provides insights about the market driving forces, potential opportunities, customer’s demands and requirement which in turn help the companies to come up with new strategies in order to survive in the long run competition. The quantitative segment offers the most credible information related to the industry. Based on the data gathering, we use to derive the market size and estimate their future growth prospects on the basis of global, region and country.

Our market research process involves with the four specific stages.

Data Collection
Data Synthesis
Market Deduction & Formulation
Data Screening & Validation

Data Collection: This stage of the market research process involves with the gathering and collecting of the market/industry related data from the sources. There are basically two types of research methods:

Primary Research: By conducting primary research, it involves with the two types of data gathering; exploratory and specific. Exploratory data is open-ended and helps us to define a particular problem involving surveys, and pilot study to the specific consumer group, knowing their needs and wants catering to the industry related product/service offering. Explanatory data gathering follows with the bit of unstructured way. Our analyst group leads the study by focusing on the key crowd, in this manner picking up bits of knowledge from them. In light of the points of view of the clients, this data is used to plan advertise techniques. In addition, showcase overviews causes us to comprehend the current scenario of the business. Specific data gathering on the hand, involves with the more structured and formal way. The primary research usually includes in telephonic conversations, E-mail collaborations and up close and personal meetings/interviews with the raw material suppliers, industrial wholesalers, and independent consultants/specialists. The interviews that we conduct offers important information on showcase size and industry development patterns. Our company likewise conducts interviews with the different business specialists so as to increase generally bits of knowledge of the business/showcase.
Secondary Research: The secondary research incorporates with the data gathering from the non-profit associations and organizations, for example, World bank, WHO, investor relations and their presentations, statistical databases, yearly(annual reports) reports, national government records, factual databases, websites, articles, white papers, press releases, blogs and others. From the annual report, we deduce an organization's income/revenue generation to comprehend the key product segment related to the market. We examine the organization sites and implement product mapping strategy which is significant for determining the segment revenue. In the product mapping technique, we choose and categorize the products offered by the companies catering to the industry specific market, derive the segment revenue for each of the organizations to get the market estimation. We also gather data & Information based on the supply and demand side of the value chain involved with the domain specific market. The supply side denotes the distributors, wholesalers, suppliers and the demand side denotes the end-consumers/customers of the value chain. The supply side of the market is analyzed by examining the product growth across industry in each of the region followed by its pricing analysis. The demand side is analyzed by the evaluating the penetration level and adoption rates of the product by referring to the historical/past data, examine the present usage and forecasting the future trends.
Purchased Database: Our purchased data provides insights about the key market players/companies along with their financial analysis. Additionally, our data base also includes market related information.

We also have the agreements with various reputed data providers, consultants and third party vendors who provide information which are not limited to:

Export & Import Data
Business Information related to trade and its statistics
Penetration level of a particular product/service based on geography mainly focusing on the unmet prerequisites of the customers.

In-house Library: Apart from these third-party sources, we have our in-house library of quantitative and qualitative data & information. Our in-house database includes market data for various industry and domains. These data are updated on regular basis as per the changing market scenario. Our library includes, internal audit reports, historic databases, archives and journal publications. Sometimes there are instances where there is no metadata or raw data available for any domain specific market. For those particular cases, we utilize our expertise to forecast and estimate the market size in order to generate comprehensive data sets. Our analyst team adopts a robust research technique in order to deduce the market size and its estimates:
Examining demographic along with psychographic segmentation for market evaluation
Analyzing the macro and micro-economic indicators for each demography
Evaluating the current industry trends popular in the market.

Data Synthesis: This stage includes the evaluation and assessment of all the data acquired from the primary and secondary research. It likewise includes in evaluating the information for any disparity watched while information gathering identified with the market. The data & information is gathered with consideration to the heterogeneity of sources. Scientific and statistical methods are implemented for synthesizing dissimilar information sets and provide the relevant data which is fundamental for formulating strategies. Our organization has broad involvement with information amalgamation where the information goes through different stages:

Information Screening: Information screening is the way toward examining information/data gathered from the sources for errors/mistakes and amending it before data integration process. The screening includes in looking at raw information, identifying and distinguishing mistakes and managing missing information. The reason for the information screening is to ensure information is effectively entered or not. Our organization utilizes objective and precise information screening grades through repetitive quality checks.
Data Integration: The data integration method involves with the incorporation of numerous information streams. The data streams is important so as to deliver investigate examines that give overall market scenario to the investors. These information streams originate from different research contemplates and our in house database. After the screening of the information, our analysts conduct efficient integration of the data streams, optimizing connections between integrated surveys and syndicated data sources. There are two research approaches that we follow so as to coordinate our information; top down methodology and bottom up methodology.

Top-down analysis generally refers to using broad factors as a basis for decision making. The top-down approach helps in identifying the overall market scenario along with the external and internal factors effecting the market growth.

The bottom-up approach takes a completely different approach. Generally, the bottom-up approach focuses its analysis on micro attributes and specific characteristics of the domain specific market.

Market Formulation & Deduction: The last stage includes assigning the data & information in a suitable way in order to derive market size. Analyst reviews and domain based opinions based on holistic approach of market estimation combined with industry investigation additionally features a crucial role in this stage.

This stage includes with the finalization of the market size and numbers that we have gathered from primary and secondary research. With the data & information addition, we ensure that there is no gap in the market information. Market trend analysis is finished by our analysts by utilizing data extrapolation procedures, which give the most ideal figures to the market.

Data Validation: Validation is the most crucial step in the process. Validation & re-validation through scientifically designed technique and process that helps us finalize data-points to be used for final calculations. This stage also involves with the data triangulation process. Data triangulation generally implicates the cross validation and matching the data which has been collected from primary and secondary research methods.

Please fill the form below, to recieve the report sample

Full Name

Country

Phone

Company

Designation

Comment

Human Verification

Our Clients

Choose License Type

For more information

Have a Question? Email us at

sales@fiormarkets.com

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery

Testimonials

Hi John,
Thanks for the report. We've been going through it and see some good data on the market and players. –

Kennedy Brown
Health Technology Innovation
United States

Hi Rahul,
Thank You for the report it is good and beneficial for me.
Thank You in Advance

Mika Salomäki

Dear Siddhartha,
Thank you for your fast reply. The report arrived safe and sound, evrything looks all right.
Thank you very much for your assitance and I will be looking forward to another opportunity for cooperation.

ONDŘEJ ŠUPKA
Analytics Department
ČESKÁ ZBROJOVKA A.S.

Dear Siddhartha,
The report looks good, and we believe the material mix is more realistic now. It is good to know you report “Net” Manufacturing Selling Price, as that can make a difference in how we view the numbers. The reports were great and we appreciate your working with us.
Thanks for all your help!